GE Healthcare and Vanderbilt University Medical Center announced a five-year partnership to develop diagnostic tools that use artificial intelligence (AI) to predict the safety and efficacy of immunotherapy treatments before offering them to patients.
Together, GE and Vanderbilt will conduct a retrospective study to investigate the response of thousands of cancer patients to different immunotherapy treatments. They will use the data to develop AI applications designed to facilitate the identification of the most suitable treatment for individual patients.
In addition, GE and Vanderbilt are developing new PET imaging tracers to help physicians determine which cancer patients may safely participate in clinical immunotherapy trials. GE is also collaborating with the Vanderbilt-Ingram Cancer Center on methods to improve stem cell transplantation, beginning with automating processes and digitizing workflows.
